Implantation Technique for the Aeson Total Artificial Heart

Q3 Medicine

Operative Techniques in Thoracic and Cardiovascular Surgery Pub Date : 2024-06-01 DOI:10.1053/j.optechstcvs.2024.01.002

André Vincentelli MD, PhD , Yuriy Pya MD , Ivan Netuka MD, PhD , Assad Haneya MD, PhD , Jan Schmitto MD, PhD , Michel Kindo MD, PhD , Peter Wearden MD, PhD , Piet Jansen MD, PhD , Christian Latremouille MD, PhD

{"title":"Implantation Technique for the Aeson Total Artificial Heart","authors":"André Vincentelli MD, PhD , Yuriy Pya MD , Ivan Netuka MD, PhD , Assad Haneya MD, PhD , Jan Schmitto MD, PhD , Michel Kindo MD, PhD , Peter Wearden MD, PhD , Piet Jansen MD, PhD , Christian Latremouille MD, PhD","doi":"10.1053/j.optechstcvs.2024.01.002","DOIUrl":null,"url":null,"abstract":"<div><p>The autoregulated, pulsatile Aeson total artificial heart (Carmat SA, Vélizy, France) is a single-unit biventricular device. The central body comprises the 2 blood pumping ventricles and separate technical compartments which house 2 electrohydraulic pumps and control electronics which employ an algorithm informed by pressure sensors and volume detection transducers in each ventricle. The prosthesis is connected by an 8 mm driveline, which exits the skin in the lower right quadrant, to an external routing module and a controller powered by batteries. Since the first implantation took place in 2013, more than 50 patients have been successfully implanted during clinical studies, and commercially after the Aeson obtained its CE mark in 2020, as a bridge to transplant device. The size of the device and the lack of adhesions around the device body have been shown to facilitate relatively easy explanation and subsequent transplantation.</p><p>With the growing experience, the implant procedure has evolved from experimental to a well-established routine procedure. The purpose of this article is to provide a guide for potential implanters in order to ensure that the advanced design benefits of the Aeson TAH are realized by incorporating optimal surgical techniques.</p></div>","PeriodicalId":35965,"journal":{"name":"Operative Techniques in Thoracic and Cardiovascular Surgery","volume":"29 2","pages":"Pages 149-167"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1522294224000047/pdfft?md5=24bdf33bbcc8b2e7b8976019caf1387c&pid=1-s2.0-S1522294224000047-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Operative Techniques in Thoracic and Cardiovascular Surgery","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1522294224000047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The autoregulated, pulsatile Aeson total artificial heart (Carmat SA, Vélizy, France) is a single-unit biventricular device. The central body comprises the 2 blood pumping ventricles and separate technical compartments which house 2 electrohydraulic pumps and control electronics which employ an algorithm informed by pressure sensors and volume detection transducers in each ventricle. The prosthesis is connected by an 8 mm driveline, which exits the skin in the lower right quadrant, to an external routing module and a controller powered by batteries. Since the first implantation took place in 2013, more than 50 patients have been successfully implanted during clinical studies, and commercially after the Aeson obtained its CE mark in 2020, as a bridge to transplant device. The size of the device and the lack of adhesions around the device body have been shown to facilitate relatively easy explanation and subsequent transplantation.

With the growing experience, the implant procedure has evolved from experimental to a well-established routine procedure. The purpose of this article is to provide a guide for potential implanters in order to ensure that the advanced design benefits of the Aeson TAH are realized by incorporating optimal surgical techniques.

查看原文本刊更多论文

Aeson 全人工心脏的植入技术

自动调节、搏动式 Aeson 全人工心脏（Carmat SA，法国韦利齐）是一种单体双心室装置。中央主体由两个泵血心室和独立的技术舱组成，技术舱内装有两个电液泵和控制电子装置，控制电子装置采用的算法由每个心室中的压力传感器和容积检测传感器提供信息。假体通过一条从右下象限皮肤穿出的 8 毫米动力线与外部路由模块和由电池供电的控制器相连。自 2013 年首次植入以来，已有 50 多名患者在临床研究中成功植入了假体，2020 年 Aeson 获得 CE 标志后，该假体作为移植手术的桥梁设备投入商业使用。该装置的尺寸和装置体周围无粘连的特点已被证明有利于相对简便的解释和后续移植。随着经验的不断积累，植入程序已从实验性程序发展为成熟的常规程序。本文旨在为潜在的植入者提供指导，以确保通过采用最佳手术技术实现 Aeson TAH 先进的设计优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Operative Techniques in Thoracic and Cardiovascular Surgery Medicine-Surgery

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： Operative Techniques in Thoracic and Cardiovascular Surgery provides richly illustrated articles on techniques in thoracic and cardiovascular surgery written by renowned surgeons. Each issue presents cardiothoracic topics in adult cardiac, congenital, and general thoracic surgery. Each specialty of interest to the thoracic and cardiovascular surgeon is explored through two different approaches to a specific surgical challenge. Each article is thoroughly illustrated with original line drawings, actual intraoperative photos, and supporting tables and graphs.